Deciphering the Role of Glutamate Signaling in Glioblastoma Multiforme: Current Therapeutic Modalities and Future Directions

Curr Pharm Des. 2020;26(37):4777-4788. doi: 10.2174/1381612826666200603132456.


As the most popular intrinsic neoplasm throughout the brain, glioblastoma multiforme (GBM) is resistant to existing therapies. Due to its invasive nature, GBM shows a poor prognosis despite aggressive surgery and chemoradiation. Therefore, identifying and understanding the critical molecules of GBM can help develop new therapeutic strategies. Glutamatergic signaling dysfunction has been well documented in neurodegenerative diseases as well as in GBM. Inhibition of glutamate receptor activation or extracellular glutamate release by specific antagonists inhibits cell development, invasion, and migration and contributes to apoptosis and autophagy in GBM cells. This review outlines the current knowledge of glutamate signaling involvement and current therapeutic modalities for the treatment of GBM.

Keywords: Glioblastoma multiforme; antagonist; apoptosis; current therapeutic modalities; glutamate; invasion.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Apoptosis
  • Brain Neoplasms* / drug therapy
  • Cell Line, Tumor
  • Glioblastoma* / drug therapy
  • Glutamates
  • Humans
  • Neoplasm Invasiveness
  • Signal Transduction


  • Glutamates